Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.48 USD
+0.04 (2.78%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.61 +0.13 (8.78%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
Adicet Bio, Inc. [ACET]
Reports for Purchase
Showing records 1 - 20 ( 112 total )
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- Going for the Gold Medal: Cell Therapy in Autoimmune Disease
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ADI-001 LN Data in 1H:25; Development Expanding
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Allo, Bringing New Potluck Dishes to the II CART
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
IND Cleared for ADI-270 in r/r RCC; First Look in 1H:25
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy Deep Dive: Turning the Tide From Oncology to Autoimmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Phase 1 Trial of ADI-001 in Lupus Nephritis to Initiate This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
EHA 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2024: ADI-270 Showing High Target Sensitivity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Phase 1 GLEAN Study Continues to Enroll MCL Patients; ADI-001 Expanding into Autoimmune Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; ADI-001 and ADI-270 Remain on Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R